Oxford Biomedica (LON:OXB) Lowered to “Hold” Rating by Deutsche Bank Aktiengesellschaft

Oxford Biomedica (LON:OXB) was downgraded by analysts at Deutsche Bank Aktiengesellschaft to a “hold” rating in a research report issued to clients and investors on Tuesday,Digital Look reports. They presently have a GBX 595 target price on the biopharmaceutical company’s stock, down from their prior target price of GBX 800. Deutsche Bank Aktiengesellschaft’s target price suggests a potential upside of 22.05% from the company’s previous close.

Several other equities research analysts have also recently weighed in on the company. Royal Bank Of Canada decreased their price target on Oxford Biomedica from GBX 1,140 to GBX 900 and set an “outperform” rating for the company in a research note on Monday, August 10th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 8.27 target price on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of GBX 580.85.

Oxford Biomedica Stock Performance

Shares of LON:OXB opened at GBX 487.50 on Tuesday. The company has a quick ratio of 1.67, a current ratio of 2.20 and a debt-to-equity ratio of 162.16. Oxford Biomedica has a 12-month low of GBX 441.50 and a 12-month high of GBX 952. The firm has a market cap of £590.06 million, a PE ratio of -18.11 and a beta of 1.10. The company’s 50 day moving average price is GBX 588.11 and its two-hundred day moving average price is GBX 631.69.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.